Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
Follow her on Twitter @megtirrell.
CNBC's Meg Tirrell reports on the biggest health issues and how industry leaders are thinking about the future of health care in America. David Gluckman, Lazard co-head of health care, weighs in.
CNBC's Meg Tirrell reports on Puma's stock spike after the FDA board votes in support of its breast cancer drug.
CNBC's Meg Tirrell reports on the FDA approving Puma Biotech's breast cancer drug, which sent shares of the company higher.
CNBC's Meg Tirrell reports Neurocrine's stock fell after hours following reports it's drug trial for a new Tourette's medication had failed.
Jeff Leiden, Vertex Pharmaceuticals CEO, speaks to CNBC's Meg Tirrell about his company's cystic fibrosis drugs and the future for biotech and pharma under the current administration.
CNBC's Meg Tirrell reports on Amgen stocks falling today after a drug risk.
CNBC's Meg Tirrell talks to Francis deSouza, Illumina CEO, about the future of genome sequencing, growth and government science funding.
Elliott, the activist hedge fund led by Paul Singer, disclosed a large holding in Athenahealth, which provides electronic-health records.
CNBC's Meg Tirrell reports on the major names making waves in cancer research ahead of the American Society of Clinical Oncology conference.
CNBC's Meg Tirrell reports on the drug stocks reacting to the data dump. The "Fast Money" traders weigh in.